Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amibegron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 known ✓ | P13945 | 12/20 | 0.89 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amibegron SCHEMBL9316758 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL2335210 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3897916 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL29380172 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL2335205 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9317343 | 1.00 | ADRB3 (0.89) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3898164 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL3824162 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL9006793 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 | |
| Amibegron SCHEMBL8765764 | 0.99 | ADRB3 (0.91) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1382333-B1 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | ASTELLAS PHARMA INC (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-6992211-B2 | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same | SANOFI-AVENTIS (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20040180953-A1 | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| US-20010025038-A1 | Administering to the mammal an effective amount of a D1/D5 (dopamine) antagonist or a D1/D5 partial agonist for reducing cravings of food or an addictive substance | COFFIN VICKI L (US) | 2001-09-27 | — | — | US | disclosed |
| US-6262049-B1 | REDUCING THE CRAVINGS OF A MAMMAL TO ANY DOPAMINE MEDIATED CRAVINGS INCLUDING FOOD OR ADDICTIVE SUBSTANCES. | SCHERING CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-0801059-B1 | INDOLE DERIVATIVE | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-06-27 | — | — | EP | disclosed |
| EP-1043980-A2 | METHOD OF REDUCING CRAVING IN MAMMALS | SCHERING CORPORATION (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999021540-A2 | METHOD OF REDUCING CRAVING IN MAMMALS | SCHERING CORPORATION (US) | 1999-05-06 | — | — | WO | disclosed |
| US-5817689-A | ADRENERGIC RECEPTOR-STIMULATING AGENT, OBESITY, DIABETES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-10-06 | — | — | US | disclosed |
| EP-0801059-A1 | INDOLE DERIVATIVE | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1997-10-15 | — | — | EP | disclosed |
| US-5627200-A | β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia | PFIZER INC (US) | 1997-05-06 | — | — | US | disclosed |
| US-5347037-A | (RR) and (RS stereoisomers of N-(7-ethoxycarbonylmethoxy-1,2,3,-tetrahydronaphth-2-yl)-2-(3-chlorophenyl)-2-hydroxyethanamine and their pharmaceutically acceptable salts | SANOFI (FR) | 1994-09-13 | — | — | US | disclosed |
| US-5041606-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI | 1991-08-20 | — | — | US | disclosed |
| US-4927955-A | Process for the O-alkylation of N-(hydroxy)aralkylphenylethanolamines | SANOFI (FR) | 1990-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | ADRB3 12/4885ADRB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.